the use of aerosolized corticosteroid drugs in patients with chronic bronchial asthma. The hope is that a local effect on the bronchial mucosa will occur, thereby reducing the total daily steroid dose required and obviating some of the undesirable side effects of oral steroid administration.
T HERE HAS BEEN RECENT INTEREST IN
the use of aerosolized corticosteroid drugs in patients with chronic bronchial asthma. The hope is that a local effect on the bronchial mucosa will occur, thereby reducing the total daily steroid dose required and obviating some of the undesirable side effects of oral steroid administration.
The first report, by Gelfand1 in 195 1, showed a favorable response in four of five patients with bronchial asthma after four days of therapy with aerosolized cortisone acetate solution in a total daily dose of 50 mg. Subsequent trials with aerosolized hydrocortisone hemisuccinate solution failed to confirm such success.'" However, clinical evaluation of relatively insoluble hydrocortisone acetate as an aerosolized powder was reported to show definite improvement in 50 to 82 per cent of asthmatics;" comparable clinical results have been reported with aerosolized prednisolone phosphate by some a~thors.'"~ There have been only a few objective studies of aerosolized steroids using pulmonary function tests. Morrison Smith,' using the forced expiratory volume for 0.75 second, was unable to find a significant benefit in asthmatic children with hydrocortisone hemisuccinate solution as compared with placebo. Langlands and McNeill" evaluated ten chronic asthmatics on hydrocortisone acetate powder and placebo. They were unable to demonstrate improvement in the lung volumes, forced expiratory spirograms or distribution of inspired air in the treated group over the placebo group. Franklin et al? utilized spirograrns in addition to clinical evaluation of their patients. They concluded that their patients demonstrated marked improvement, but did not present their ventilatory function data.
The present study attempts to evaluate the bronchodilator effect of aerosolized dexamethasone phosphate in 26 patients with chronic asthma, utilizing the forced expiratory volume for 1.0 second (FEV1.o) , also known as the one second vital capacity, and the peak expiratory flow rate (PEFR) as indices of ventilatory function.
The peak expiratory flow rate is the maximum instantaneous velocity of air flow attained during a forced expiration following a full inspiration. the preceding three months. There were four men and 22 women with ages ranging from 14 to 72 years. There was one with allergic bronchial asthma, four with infectious asthma and 21 with mixed asthma. Six produced no sputum, four small amounts (less than 15 ml./day), and 16 produced more than 15 ml. of sputum daily.
The vital capacity (VC) and FEV1.o were determined using the Gaensler-Collins Vitalometer. The PEFR was determined using the Wright Peak Flo~meter.'~ All determinations were repeated until there was close agreement between the two highest, and the maximum value was used for study The At the first visit, 14 patients were studied before and after the inhalation of 0.3 ml.
of one-half per cent isoproterenol aerosol. All 26 returned to the pulmonary function laboratory on Mondays, Wednesdays, and Fridays for ventilatory function tests for a total of six visits. This two-week period of observation constituted control period I (Fig. 1 ) . O n three or more occasions during this two-week period, each patient was asked about the amount of medication taken and the nature and severity of the asthma. They were then placed on dexamethasone aerosol inhalations, administered from a pressurized inhaler containing dexamethasone as a finely divided suspension in fluorochlorohydrocarbon propellant containing two per cent ethanol and sorbitan trioleate. The latter is a wetting agent used to provide better dispersal of the suspension. The inhaler delivered approximately 0.084 mg. of dexamethasone free alcohol for each actuation of its valve. They were instructed to take three inhalations four times daily, regardless of the severity of symptoms, for a total daily dose of 1.0 mg. They were also instructed not to take additional inhalations of the drug even if symptoms became worse. Ephedrine orally, isoproterenol aerosol and aminophylline rectally were used as indicated throughout the period of study. An attempt was made to keep a careful record of all medication used during the various study periods. The treatment period with dexamethasone aerosol was continued for a minimum of two weeks. During this time they were seen by a physician on at least three occasions, and a record was made on a standard form of the amount of bronchodilator drugs taken since the last visit. The severity of asthma was also recorded on the basis of patient's statements and physical examination of the chest.
A second control period of one week, or three to four observation periods, was then carried out in 12 patients after dexamethasone aerosol was discontinued (control period 11, Fig. 1 ). This was followed by a second period of treatment using a pressurized inhaler containing isoproterenol sulfate in addition to dexamethasone. This inhaler delivered .084 mg. of dexamethasone free alcohol and approximately 0.10 mg. of isoproterenol sulfate for each actuation of its valve. Clinical and ventilatory function observations were made three times weekly as noted above. Following this second period of treatment with dexamethasone and isoproterenol aerosol, nine 
Severity of Asthma
Severity of airway obstruction was graded by analysis of the FEVt.0 during control period I. Obstructive disease was considered to be mild if the FEVt.0 was greater than 75 per cent of predicted, moderate if it was from 51 to 75 per cent, severe if it was from 26 to 50 per cent, and very severe if it was less than 25 per cent of predicted. In the total group of 26 patients, there were five who were classified as mild, nine moderate, ten severe and two very severe.
Criteria of Significant Change
Significant change in the severity of airway obstruction was considered to have A significant change in VC without a change in either the PEFR or FEV1.o was not considered indicative of bronchodilation. Potential Ability to Respond to Bronchodilator Therapy Potential ability to respond to bronchodilator therapy was judged on the basis of two criteria: the ability to respond acutely to bronchodilator aerosol and the day to day variation in severity of asthma during the control and treatment periods (Figs. 2 and 3 ) .
Nine of the 14 patients who were studied after the administration of isoproterenol aerosol in the first control period showed significant improvement in airway obstruction. The five who did not respond significantly and 11 of the 12 not studied after isoproterenol aerosol showed a 20 per cent variation or greater in the FEV1.o or the PEFR with or without changes in VC 
Side Efects of Dexamethasone Aerosol
showed a significant response while on dexUntoward symptoms were observed on amethasone aerosol as compared with conthree occasions. TWO patients vomited imtrol period I. In two, the results were strikmediately after taking the aerosol. Howing. Of the ten responding to therapy, three ever, they had previously had similar sympwere graded as moderate, six as severe and toms after taking other medication and the one as very severe. Thus, of the ten in emesis was not -considered to be drug-inthe severe ind very severe group (Table  duced. One of them completed five of the 1 ), more than half showed a significant six observations on dexamethasone aerosol response while on dexamethasone aerosol. and is included in the analysis; the other Evaluation of ventilatory function data on is not. The third complained of increased 12 patients during control period I1 showed obstructive dyspnea after dexamethasone one improved, two worse, and nine un- satisfying evaluation of the patients' response to drug therapy. This was due in changed as compared with control period part to marked day to day variation in 1. Control period 11, when compared with the severity of asthma and in part to great the dexamethasone period, showed none difficulty in determining precisely how improved, six worse and six unchanged much medication patients had taken from (Fig. 4 ) .
week to week. Of 21 who could be evalu-A comparison of dexamethasone-isoproated, 11 were classified as better, eight as terenol aerosol with dexamethasone aerosol the same and two as worse. in 11 showed two patients improved, one worse, and eight unchanged. However, in DISCUSSION comparison with control period 11, seven
Quantitative methods are essential in were improved, none was worse and five evaluating the effect of drugs in bronchial asthma unless the response to a particular agent is dramatic. The problem is further complicated with corticosteroid drugs, because clinical improvement may frequently be related to a systemic or tonic action rather than to a specific effect on the bronchi.
In choosing a method of evaluating airway obstruction in asthma, the striking day-to-day variations must be borne in mind. It seems unreasonable to expect once-weekly testing to be representative of the entire preceding period. In an attempt to overcome these difficulties, we decided to base our evaluation of dexamethasone aerosol primarily on objective tests of ventilatory function, using thrice weekly observations of FEV1.o and PEFR.
The FEV1.o and PEFR are simple to perform and have been shown to increase after the administration of known bronchodilator drugs.'Vrevious studies have shown that it may be misleading to rely on a single test in evaluating a bronchodilator agent, since one test may show bronchodilation while another does not" An evaluation was made of the relative direction of change of 46 1 paired observations of PEFR and FEV1.o. In 81 per cent of observations, the direction of change was the same, in 19 per cent it was different. The use of at least two physiologic indices in objectively evaluating bronchodilator drugs has thus been confirmed.
This study was designed without the use of a placebo for several reasons. First, we have been unable to obtain a satisfactory placebo which could be used in a blind study since the distinctive bitter taste of the steroid used is difficult to reproduce. In all of the papers reporting the use of placebo in blind studies, either the type of placebo used was not mentioned or it consisted of merely the vehicle without the steroid. Only HajosS attempted to reproduce this bitter taste by adding quinine. Second, most of the patients admitted to this study were quite ill and it was considered that the use of a placebo in this group might entail risk. Needless to say, we recognize that in the present study there were many variables in addition to the administration of steroid aerosol.
We obtained striking physiologic improvement in only two of 23 patients, with less striking improvement seen in eight additional patients. It seems significant that of 12 patients studied after dexamethasone aerosol was discontinued, six became worse, while none improved. The proportion of patients responding to dexamethasone-isoproterenol aerosol (seven of 12 ) was not appreciably larger than the proportion responding to dexamethasone aerosol ( 10 of 23 ) . The degree of improvement was also the same in the two groups Rebound worsening following cessation of steroid aerosol apparently is not of major concern since in only two instances out of 21 compared, did a control period following steroid aerosol show worsening when compared with a control period preceding it. Most of our patients were of the "wet" type, that is, producing daily sputum; many had an infectious component. Helm and Heyworth" have pointed out that their results were disappointing in chronic asthma and in patients with bronchial infection. Herxheimer et al.' also feel that the infectious type is less likely to respond than the allergic type and that hypersecretion is a handicap, possibly because of obstruction to the inhalation of the aerosol by bronchial exudate. HajosS attempted to circumvent this difficulty by first aspirating secretions with a bronchial catheter and by the use of aerosolized hyaluronidase. We were unable to find a relationship in this study betwen quantity of sputum produced and a response to dexamethasone aerosol.
Side effects of dexamethasone aerosol were minimal. However, in addition to the one patient reported in this series, we have seen several patients who developed exacerbation of airway obstruction immediately after the aerosol. Others'Qave also noted similar effects. This manifestation has not Diseases of the Chest been observed with the dexamethasoneisoproterenol mixture. In addition, we have observed one case of thrush after prolonged administration of dexamethasone-isoproteren01 aerosol. While there is no doubt that much of the steroid administered by aerosol reaches the blood stream,P'17"\nd may well exert a systemic effect, most authors feel that the total daily dose used in the aerosolized form is considerably less than that effective orally. Our patients received about one unit of dexamethasone (one unit is equivalent to 25 mg. of cortisone) which is less than the oral maintenance dose usually required in such patients.
Helm and Heyworth'' observed their best results in acute asthma with symptomfree intervals and suggested that a prime use of steroid aerosol was in this situation. It is our feeling that the need for aerosolized steroids arises because of the toxicity of prolonged oral corticosteroid therapy in chronic asthma. If this form of treatment is to assume an important role in our armamentarium, it must prove its usefulness on a maintenance basis rather than as intermittent therapy; that is, either as a substitute for prolonged oral therapy or as an adjunctive agent in withdrawing patients from oral steroid maintenance.
The results of aerosol dexamethasone therapy were not dramatic in this study, but most of the patients responding had the more severe degrees of airway obstruction. Although a limited role seems likely for this form of therapy, further controlled clinical trial appears to be warranted. SUMMARY 1. The bronchodilator effect of dexamethasone aerosol was evaluated in a controlled study in 26 patients with chronic asthma. The forced expiratory volume for one second and the peak expiratory flow rate were used as indices of airway obstruction. Measurements were made three times a week for periods of four to eight weeks.
Ten of 23 patients (43 per cent)
showed a significant response while on dexamethasone aerosol; there was no rebound worsening after cessation. Most of the patients responding had the more severe degrees of airway obstruction.
3.
The only significant side-effect was exacerbation of airwav obstruction in one patient. This was not seen with a dexamethasone-isoproterenol mixture.
These results appear to warrant further controlled clinical trial of dexamethasone aerosol. 
